首页 › 肾癌（肾细胞癌） › 哥伦比亚特区 › Washington
Washington DC 肾癌（肾细胞癌）临床试验
13项针对 肾癌（肾细胞癌）的研究正在 Washington及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
招募中2 期
- National Institutes of Health Clinical Center, Bethesda · 距离 7 英里
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 距离 7 英里
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
招募中2 期
- MedStar Georgetown University Hospital, Washington D.C.
- National Institutes of Health Clinical Center, Bethesda · 距离 7 英里
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
招募中2 期
- NCI - Center for Cancer Research, Bethesda · 距离 7 英里
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
招募中1/2 期
- Sibley Memorial Hospital, Washington D.C.
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
招募中2 期
- Georgetown University, Washington D.C.
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
招募中3 期
- MedStar Washington Hospital Center, Washington D.C.
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
招募中观察性研究欢迎健康志愿者
- National Institutes of Health Clinical Center, Bethesda · 距离 7 英里
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
招募中1/2 期
- National Institutes of Health Clinical Center, Bethesda · 距离 7 英里
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
招募中观察性研究
- National Institutes of Health Clinical Center, Bethesda · 距离 7 英里
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
招募中1/2 期
- National Institutes of Health Clinical Center, Bethesda · 距离 7 英里
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
招募中2 期
- Sibley Memorial Hospital, Washington D.C.
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
招募中3 期
- MedStar Washington Hospital Center, Washington D.C.
其他城市的 肾癌（肾细胞癌）试验
- Houston, TX35 项研究
- New York City, NY27 项研究
- Dallas, TX23 项研究
- Nashville, TN23 项研究
- St. Louis, MO23 项研究
- Los Angeles, CA20 项研究
- Boston, MA16 项研究
- Baldwin Park, CA16 项研究
- Pittsburgh, PA15 项研究
- Philadelphia, PA15 项研究
- Queens, NY15 项研究
- Jacksonville, FL14 项研究
Washington的其他研究
- 癌症（所有类型）58 项研究
- 非小细胞肺癌55 项研究
- 乳腺癌46 项研究
- 转移性癌症43 项研究
- 肺癌41 项研究
- 前列腺癌38 项研究
- 肥胖症33 项研究
- 结直肠癌29 项研究
- 心血管疾病28 项研究
- 膀胱癌26 项研究
- 急性髓系白血病24 项研究
- 卵巢癌23 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。